TransMedics Group, Inc. (TMDX)
NASDAQ: TMDX · Real-Time Price · USD
94.18
+1.93 (2.09%)
Apr 24, 2025, 4:00 PM EDT - Market closed
TransMedics Group Revenue
In the year 2024, TransMedics Group had annual revenue of $441.54M with 82.74% growth. TransMedics Group had revenue of $121.62M in the quarter ending December 31, 2024, with 49.83% growth.
Revenue (ttm)
$441.54M
Revenue Growth
+82.74%
P/S Ratio
7.09
Revenue / Employee
$606,511
Employees
728
Market Cap
3.19B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 441.54M | 199.92M | 82.74% |
Dec 31, 2023 | 241.62M | 148.16M | 158.53% |
Dec 31, 2022 | 93.46M | 63.20M | 208.83% |
Dec 31, 2021 | 30.26M | 4.62M | 18.03% |
Dec 31, 2020 | 25.64M | 2.04M | 8.62% |
Dec 28, 2019 | Pro | Pro | Pro |
Dec 29, 2018 | Pro | Pro | Pro |
Dec 30, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 30, 2006 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.90B |
TMDX News
- 14 hours ago - TransMedics to Report First Quarter 2025 Financial Results on May 8, 2025 - PRNewsWire
- 21 hours ago - TransMedics Group, Inc. (TMDX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - Accesswire
- 2 days ago - TransMedics: Get Some Exposure Despite Market Concerns - Seeking Alpha
- 2 days ago - Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against TransMedics Group, Inc. (TMDX) and Encourages Stockholders to Learn More About the Investigation - Accesswire
- 4 days ago - Bronstein, Gewirtz & Grossman, LLC Encourages TransMedics Group, Inc. (TMDX) Investors to Inquire about Securities Investigation - Accesswire
- 7 days ago - Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against TransMedics Group, Inc. (TMDX) And Encourages Investors to Reach Out - Accesswire
- 13 days ago - TMDX STOCK FRAUD: Did TransMedics Group Commit Securities Fraud? Investors are Notified to Contact BFA Law by the April 15 Court Deadline (NASDAQ:TMDX) - GlobeNewsWire
- 14 days ago - DEADLINE NEXT WEEK: Berger Montague Advises TransMedics (NASDAQ: TMDX) Investors to Contact the Firm Before April 15, 2025 - GlobeNewsWire